MARKET

URGN

URGN

Urogen Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.32
-0.09
-0.40%
After Hours: 22.32 0 0.00% 16:00 10/18 EDT
OPEN
22.28
PREV CLOSE
22.41
HIGH
22.79
LOW
22.09
VOLUME
133.50K
TURNOVER
--
52 WEEK HIGH
55.49
52 WEEK LOW
20.72
MARKET CAP
466.44M
P/E (TTM)
-4.5003
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of URGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

URGN News

  • Are These 3 Beaten-Down Biotech Stocks Bargains Now?
  • MotleyFool.com.3d ago
  • The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
  • Benzinga.10/10 11:31
  • The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
  • Benzinga.10/09 11:58
  • The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
  • Benzinga.10/08 11:11

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About URGN

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
More

Webull offers Urogen Pharma Ltd (URGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.